OPHTHOTECH

Ophthotech Corp.
Investor Relations Department
Five Vaughn Drive
Suite 106
Princeton, NJ 08540
United States

Visit IR website
Sign-up for email alerts

NASDAQ: OPHT [1]	
Last Trade:	2.90
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.24 - 65.96
Volume	N/A
Market Cap. ($M)	103.965
Shares Out (M)	35.850

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

… (more)

Stock Performance



Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

First Quarter Financial Results

Feb 28, 2017
Annual Report (10-K)

Apr 24, 2017
Definitive Proxy Statement

May 3, 2017
Quarterly Report (10-Q)

Nov 8, 2016
Quarterly Report (10-Q)

Aug 5, 2016
Quarterly Report (10-Q)

Nasdaq